| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-14-2023 |
| P698 | PubMed publication ID | 25609064 |
| P50 | author | Alexander M Menzies | Q57002034 |
| James S Wilmott | Q59199964 | ||
| Hojabr Kakavand | Q62749764 | ||
| John F Thompson | Q88487117 | ||
| Lauren E Haydu | Q104485018 | ||
| Ricardo E Vilain | Q114514100 | ||
| Jennifer H Yearley | Q117251005 | ||
| Richard Scolyer | Q28868730 | ||
| Georgina V. Long | Q42947998 | ||
| Richard F. Kefford | Q46460242 | ||
| P2093 | author name string | Peter Hersey | |
| P2860 | cites work | Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death | Q24293504 |
| Expression of programmed death 1 ligands by murine T cells and APC | Q28214264 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3140-3148 | |
| P577 | publication date | 2015-01-21 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients | |
| P478 | volume | 21 |
| Q36338753 | Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms |
| Q40484749 | Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? |
| Q47375181 | Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. |
| Q64882923 | Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. |
| Q52906171 | Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma |
| Q89586501 | Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density |
| Q42378351 | BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma |
| Q38783292 | Cobimetinib and vemurafenib for the treatment of melanoma |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q52618225 | Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study |
| Q100455159 | Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i |
| Q64267283 | Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials |
| Q38847989 | Contemporary and potential future molecular diagnosis of melanoma. |
| Q98226267 | Current State of Target Treatment in BRAF Mutated Melanoma |
| Q47326952 | De-novo and acquired resistance to immune checkpoint targeting. |
| Q36821164 | Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma |
| Q35862663 | Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy |
| Q33275611 | Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma |
| Q47136084 | Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed? |
| Q47125869 | High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients |
| Q98830726 | Identification of Therapeutic and Prognostic Biomarkers of Lamin C (LAMC) Family Members in Head and Neck Squamous Cell Carcinoma |
| Q39043132 | Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. |
| Q58107915 | Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy |
| Q39185608 | Mechanisms of Resistance to Immune Checkpoint Antibodies. |
| Q35918962 | MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. |
| Q48703829 | Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. |
| Q27010018 | New immunotherapies targeting the PD-1 pathway |
| Q90811847 | Nouvelles stratégies innovantes en immunothérapie |
| Q88952320 | OncoKB: A Precision Oncology Knowledge Base |
| Q92127362 | PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review |
| Q38700735 | Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. |
| Q90477375 | Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder |
| Q36693087 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q38816851 | Targeted Therapies Combined With Immune Checkpoint Therapy. |
| Q38998443 | Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. |
| Q53406743 | The Major Role of NF-kB in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q41320696 | Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. |
| Q88501993 | WITHDRAWN: Nouvelles stratégies innovantes en immunothérapie |
Search more.